The authors developed and implemented a secure chat-based pairing model to increase procedural certification and timely ...

First implantation of two alfapump patients on the same day Continuing strategy of working with Key Opinion Leaders at top tier centers Strong pipeline of additional implanting centers supports ...

Milestone in bringing breakthrough treatment option to US patients with recurrent and refractory ascites due to liver cirrhosis Feedback from hepatology community supports US market potential from ...

1 Medical Department, Kobe Detention Center, Kobe, Japan. 2 Department of Obstetrics and Gynecology, Kobe Medical Center, National Hospital Organization, Kobe, Japan. 3 Department of Internal Medicine ...

What is the aim of this Cochrane review? To find out the best available treatment for ascites (abnormal build-up of fluid in the tummy) in people with advanced liver disease (liver cirrhosis, or ...

Dublin, July 14, 2025 (GLOBE NEWSWIRE) -- The "Ascites Market - A Global and Regional Analysis: Focus on Regional and Country Analysis - Analysis and Forecast, 2025-2035" report has been added to ...

Sequana Medical NV received premarket approval from the U.S. FDA for its Alfapump system to treat recurrent or refractory ascites due to liver cirrhosis. Data from the Poseidon pivotal study showed ...

Ghent, Belgium – 23 December 2024 – Sequana Medical NV (Euronext Brussels: SEQUA, the "Company" or "Sequana Medical") , a pioneer in the treatment of drug-resistant fluid overload in liver disease, ...

The Company will be hosting a further webcast with key opinion leaders on January 8, 2025 at 3pm CET, 9am ET to discuss the US FDA approval of alfapump, the clinical need and the planned commercial US ...